Ligand Pharmaceuticals
LGND
#2815
Rank
โ‚น549.15 B
Marketcap
โ‚น27,454
Share price
-2.62%
Change (1 day)
53.83%
Change (1 year)

P/E ratio for Ligand Pharmaceuticals (LGND)

P/E ratio as of November 2026 (TTM): 113

According to Ligand Pharmaceuticals's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 113.44. At the end of 2025 the company had a P/E ratio of 30.0.

P/E ratio history for Ligand Pharmaceuticals from 2001 to 2026

PE ratio at the end of each year

Year P/E ratio Change
202530.0-101.4%
2024< -1000-8771.62%
202324.7-173.25%
2022-33.7-221.14%
202127.8-106.28%
2020-443-20949.58%
20192.13-83.05%
201812.5-91.19%
2017142-122.46%
2016-634-10933.9%
20155.85-89.6%
201456.3-3.98%
201358.6-100%
2012> 1000

P/E ratio for similar companies or competitors

Company P/E ratio P/E ratio differencediff. Country
Johnson & Johnson
JNJ
41.7-63.22%๐Ÿ‡บ๐Ÿ‡ธ USA
Pfizer
PFE
40.1-64.65%๐Ÿ‡บ๐Ÿ‡ธ USA
Eli Lilly
LLY
45.8-59.60%๐Ÿ‡บ๐Ÿ‡ธ USA
Amgen
AMGN
26.3-76.77%๐Ÿ‡บ๐Ÿ‡ธ USA
Baxter
BAX
-18.3-116.10%๐Ÿ‡บ๐Ÿ‡ธ USA
Merck
MRK
144 27.27%๐Ÿ‡บ๐Ÿ‡ธ USA
Bristol-Myers Squibb
BMY
13.6-88.04%๐Ÿ‡บ๐Ÿ‡ธ USA
GSK plc
GSK
17.1-84.91%๐Ÿ‡ฌ๐Ÿ‡ง UK
Spectrum Pharmaceuticals
SPPI
-2.86-102.52%๐Ÿ‡บ๐Ÿ‡ธ USA

How to read a P/E ratio?

The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.

Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.